BEVERLY, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics firm that has commercialized the MiQLab® System for automated multiplex PCR testing, broadcasts that it intends to amend the train worth of sure frequent share buy warrants (the “Warrants”) initially issued on October 29, 2019.
An combination of 12,769,626 Warrants have been initially issued with an train worth of CAD$0.75 per frequent share of LexaGene (a “Common Share”) in reference to a public providing of models. The Company intends to amend the train worth of unexercised Warrants to CAD$0.23 per Common Share. The Company additionally intends to lengthen the expiry date of the Warrants to November 28, 2022. All different phrases of the Warrant stay the identical.
Insiders of the Company presently maintain 2.4% of the Warrants. In accordance with TSX Venture Exchange insurance policies, the phrases of the Warrants held by insider might be amended on a professional rata foundation, such that insiders can maintain not more than 10% of the amended Warrants.
Amendment of the Warrants is topic to the approval of the TSX Venture Exchange. No motion might be required on the a part of the holders of the Warrants to give impact to the amendments.
The Warrants and the underlying Common Shares haven’t been and won’t be registered beneath the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities legal guidelines and might not be provided or bought inside the United States or to, or for the account or good thing about, a U.S. particular person (as outlined in Regulation S beneath the U.S. Securities Act) until registered beneath the U.S. Securities Act and relevant state securities legal guidelines, or an exemption from such registration is accessible. This press launch doesn’t represent a suggestion to promote or a solicitation of a suggestion to purchase any of the securities referred to herein.
To be taught extra about LexaGene and the MiQLab System or subscribe to firm updates, go to www.lexagene.com, or comply with us on Twitter or LinkedIn.
For inquiries: 800.215.1824 | [email protected] or [email protected]
For extra details about LexaGene and the MiQLab System, please go to www.lexagene.com or comply with us on Twitter or LinkedIn.
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics firm that has commercialized the MiQLab System for quick and straightforward detection of pathogens and different molecular markers. The System is designed for on-site utilization and makes use of real-time PCR chemistry. Our prospects embody biopharmaceutical firms, veterinary hospitals and reference laboratories. The MiQLab System delivers glorious sensitivity, specificity, and breadth of detection.
The TSX Venture Exchange Inc. has by no means handed upon the deserves of the proposed transaction and has neither accredited nor disapproved the contents of this press launch. Neither TSX Venture Exchange nor its Regulation Services Provider (as that time period is outlined within the insurance policies of the TSX Venture Exchange) accepts accountability for the adequacy or accuracy of this launch.
This information launch incorporates forward-looking data, which entails identified and unknown dangers, uncertainties and different elements that will trigger precise occasions to differ materially from present expectation. Important elements — together with the supply of funds, the outcomes of financing efforts, the success of expertise improvement efforts, the price to procure vital components, efficiency of the instrument, market acceptance of the expertise, regulatory acceptance, and licensing points — that might trigger precise outcomes to differ materially from the Company’s expectations as disclosed within the Company’s paperwork filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which converse solely as of the date of this press launch. The firm disclaims any intention or obligation, besides to the extent required by regulation, to replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
